New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
https://ir.definiumtx.com/news-events/press-r...ted-states
https://www.businesswire.com/news/home/20260331146931/en/
---
What they’re showing is that generalized anxiety disorder (GAD) is both larger and growing faster than a lot of people probably assume. According to their study, diagnosed prevalence went from 5.4% in 2020 to 6.6% in 2023, and when you look over a 3-year period, about 10.3% of U.S. adults have been affected. That’s basically 1 in 10 people, which is huge.
On top of that, new cases are still coming in at a steady rate (~2.1–2.3% annually), so this isn’t a static market.
Another important piece they highlight is how messy this condition actually is in the real world. About 67% of diagnosed patients are women, and there’s a high overlap with depression (MDD). That comorbidity matters because it suggests you’re not just treating “anxiety” in isolation, you’re often dealing with more complex, overlapping conditions.
The last new drug approved for GAD was in 2007, and even with current options (SSRIs/SNRIs), something like half of patients don’t get adequate relief or can’t tolerate the side effects long-term. So you’ve got a very large patient pool, with a meaningful percentage essentially underserved by existing treatments.
One subtle but important thing here is that this is based on real-world claims data (Komodo), not just surveys. It reflects actual diagnosed and treated patients, which is the kind of data that resonates more with payers and regulators down the line.
So from a strategy standpoint, this looks like DFTX doing early work on:
Payer/reimbursement positioning
Regulatory narrative (unmet need)
Commercial story for investors
It strengthens the broader thesis: big market, increasing prevalence, and a clear gap in current treatment options.
If DT-120 shows strong efficacy and durability, this kind of data helps support why it could be a meaningful player in the space rather than just another experimental therapy.
https://ir.definiumtx.com/news-events/press-r...ted-states
https://www.businesswire.com/news/home/20260331146931/en/
---
What they’re showing is that generalized anxiety disorder (GAD) is both larger and growing faster than a lot of people probably assume. According to their study, diagnosed prevalence went from 5.4% in 2020 to 6.6% in 2023, and when you look over a 3-year period, about 10.3% of U.S. adults have been affected. That’s basically 1 in 10 people, which is huge.
On top of that, new cases are still coming in at a steady rate (~2.1–2.3% annually), so this isn’t a static market.
Another important piece they highlight is how messy this condition actually is in the real world. About 67% of diagnosed patients are women, and there’s a high overlap with depression (MDD). That comorbidity matters because it suggests you’re not just treating “anxiety” in isolation, you’re often dealing with more complex, overlapping conditions.
The last new drug approved for GAD was in 2007, and even with current options (SSRIs/SNRIs), something like half of patients don’t get adequate relief or can’t tolerate the side effects long-term. So you’ve got a very large patient pool, with a meaningful percentage essentially underserved by existing treatments.
One subtle but important thing here is that this is based on real-world claims data (Komodo), not just surveys. It reflects actual diagnosed and treated patients, which is the kind of data that resonates more with payers and regulators down the line.
So from a strategy standpoint, this looks like DFTX doing early work on:
Payer/reimbursement positioning
Regulatory narrative (unmet need)
Commercial story for investors
It strengthens the broader thesis: big market, increasing prevalence, and a clear gap in current treatment options.
If DT-120 shows strong efficacy and durability, this kind of data helps support why it could be a meaningful player in the space rather than just another experimental therapy.
